## **COVID-19 STUDY Post-Exposure Prophylaxis (PEP)**

## **BACKGROUND**

More than three quarters of COVID-19 transmissions occur through close contact within households. Persons with COVID-19 can present with mild or moderate symptoms, but still be infectious. Post-exposure prophylaxis (PEP) is defined as taking a medication after being exposed or potentially exposed to an infectious agent to prevent becoming infected. Based on experience with PEP for other infections, we know that medication should be started as soon as possible after the possible exposure to prevent from getting sick.



## STUDY AIM AND TIMELINE

The COVID-19 PEP Study aims to answer the question: If someone who has been exposed to the SARS-CoV-2 virus takes a medication daily for 14 days, will the medication work to prevent them from getting sick with COVID-19/ coronavirus disease?

This study is a randomized, multi-center study of HCQ PEP for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2,000 men and women who meet the eligibility criteria from multiple sites in the United States.

Volunteers who participate in the study will be asked to take a medication, complete an online survey to assess their symptoms, and collect a sample by swabbing the inside of their nose every day for 14 days. On Day 28 a final swab will be collected and a survey completed. Volunteers will be in the study for approximately 28 days.

## JOIN THE STUDY

Go to

www.covid19pepstudy.org

For more information, visit www.covid19pepstudy.org

Enter the referral code below, answer a few questions, and submit your survey for review

Referral Code: 42-012-029

If you qualify for the study, the study team may contact you to provide additional information and to invite you to screen for the study.

Your samples may not be tested fast enough to help to provide clinical care. We are prioritizing testing of specimens for clinical care before research specimens from this study. If you are ill, please seek medical care through your regular provider. You can contact us to receive your results.



This Center for Vaccine Development and Global Health study is led by International Clinical Research Center/Department of Global Health, University of Washington, along with the UW Virology Clinic and New York University, with support from the Bill & Melinda Gates Foundation. This project is part of the COVID-19 Therapeutics Accelerator, which coordinates R&D efforts and aims to remove barriers to drug development and scale-up to address the epidemic.